摘要
目的 比较利培酮与奋乃静治疗脑血管病所致精神障碍的有效性及安全性。方法 将 63例患者按治疗药物分为两组,利培酮组(33例)和奋乃静组 (30例 ),比较两组患者的疗效及副反应。结果在治疗前两组间性别、年龄、病程、BPRS、MMSE等均无统计学差异(P>0. 05),两组在治疗前后BPRS评分均具显著性差异(35. 6±7. 3, 27. 3±6. 1,P<0. 01) (34. 9±6. 5, 28. 1±5. 7,P<0. 01),利培酮组治疗前后MMSE有显著性差异(13. 7±9. 1, 19. 5±9. 4,P<0. 05),两组间在治疗后BPRS无显著性差异(27. 3±6. 1,28. 1±5. 7,P>0. 05),而MMSE和TESS有显著性差异。结论 利培酮治疗脑血管病所致精神障碍与奋乃静疗效相当,但利培酮对认知功能的影响和安全性方面优于奋乃静。
ObjectiveTo study the efficacy and safety of Risperidone in treatment of mental disorders due to vascular disease and compare with perphenazine as a control. Method63 cases with mental disorders due to vascular disease were randomly divided into two groups receiving risperidone(n=33) or perphenazine(n=30) . ResultsBefore treatment,there were no significant differences in age, sex, course and the scores of BPRS and MMSE between two groups.There were significant change of the scores of BPRS in both groups and the scores of MMSE in group that treated with Risperidone,but there were no significant differences in the scores of BPRS between two groups.However, significant differences were found between two groups in the change about score of MMSE and TESS.ConclusionRisperidone has similar efficacy to perphenazine in treat mental disorders due to vascular disease, but risperidone has less side-effect than perphenazine and can improve cognitive function of mental disorders due to vascular disease
出处
《中国行为医学科学》
CSCD
2004年第6期635-636,共2页
Chinese Journal of Behavioral Medical Science
